Suggests meaningful reductions in hard outcomes (HF hospitalization & mortality) in HFpEF with obesity + T2D, not just symptom relief
Wu Z, Yu Y, Niu L, Fei A, Pan S
Furthermore, among those already with a SUD, GLP-1s appeared to lower hospitalizations, overdoses, and death, GLP-1 receptor agonists are not replacements for current medication treatments for AUDbut may soon become important additions
For this reason, patients with the above-mentioned long-term medication require strict dermatological and ophthalmological follow-up examinations, and patient education should also be intensified
Then, researchers discovered they have a powerful ability to help people shed unwanted pounds, as a weight loss medication, too